Eli Lilly Malaysia - Search News

Eli Lilly beats on earnings even

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped Wall Street estimates,

Reuters · 7h

Lilly reassures investors that weight-loss drug demand is strong, shares rise

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.

U.S. News & World Report · 10h

Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast

Business Insider · 11h

LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in

NBC Washington · 17h

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Free Malaysia Today2h

Wall Street ends mixed as investors digest earnings reports

NEW YORK : The S&P 500 and the Nasdaq ended higher, while the Dow closed lower after a choppy trading session on Thursday, as ...

5hon MSN

Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches

Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...

24/7 Wall St20d

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 36.07% higher than today’s price of $756.99.

22d

Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results